SCHEMBL2926852

SCHEMBL2926852

O=C(Nc1ccc2nc(CN3CCc4ccccc43)ccc2c1)c1ccc(-c2ccc(Cl)cc2)cc1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 9/20 0.56
HTR2C P28335 4/20 0.56
TNF P01375 2/20 0.53
MAPT P10636 2/20 0.51
RXFP1 Q9HBX9 1/20 0.51
NOD1 Q9Y239 2/20 0.47
NOD2 Q9HC29 1/20 0.47
MEN1 O00255 1/20 0.47
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
KMT2A Q03164 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
FAAH O00519 1/20 0.45
POLB P06746 1/20 0.44
CHRM2 P08172 1/20 0.43
CHRM4 P08173 1/20 0.43
CHRM1 P11229 1/20 0.43
CHRM3 P20309 1/20 0.43
MLLT1 Q03111 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2926277 0.95 MCHR1 (0.56) MCHR1HTR2CTNFMAPTRXFP1
SCHEMBL2924326 0.86 NOD1 (0.64) MCHR1HTR2CTNFNOD1NOD2
SCHEMBL2924502 0.82 MCHR1 (0.55) MCHR1HTR2CMEN1NPC1RAB9A
SCHEMBL2925651 0.81 MCHR1 (0.81) MCHR1HTR2CMAPTFAAHPOLB
SCHEMBL2927193 0.81 MCHR1 (0.68) MCHR1HTR2CFAAHPOLBMLLT1
SCHEMBL2925096 0.81 MCHR1 (0.80) MCHR1HTR2CMAPTFAAHPOLB
SCHEMBL2923026 0.80 MCHR1 (0.58) MCHR1HTR2CMEN1NPC1RAB9A
SCHEMBL2926412 0.80 MCHR1 (0.53) MCHR1HTR2CMAPTMEN1NPC1
SCHEMBL2925711 0.80 MCHR1 (0.64) MCHR1HTR2CMAPTMEN1NPC1
SCHEMBL2925011 0.79 MCHR1 (0.58) MCHR1HTR2CMAPTMEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1285651-B1 MELANIN CONCENTRATING HORMONE ANTAGONISTS TAKEDA PHARMACEUTICAL (JP) 2010-09-01 EP disclosed
EP-1285651-B1 MELANIN CONCENTRATING HORMONE ANTAGONISTS TAKEDA PHARMACEUTICAL (JP) 2010-09-01 EP disclosed
US-6930185-B2 Melanin-concentrating hormone antagonist TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2005-08-16 US disclosed
US-20040077628-A1 Melanin-concentrating hormone antagonist TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-04-22 US disclosed
EP-1285651-A1 MELANIN CONCENTRATING HORMONE ANTAGONISTS Takeda Chemical Industries, Ltd. (JP) 2003-02-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077628-A1 Melanin-concentrating hormone antagonist MCHR1, MC1R, MCHR2 MCHR1 1/4885HTR2C 107/4885TNF 3581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.